The Switching Antiplatelet-9 (SWAP-9) Study

Recruiting now · Phase 4

Conditions studied: Coronary Arterial Disease (CAD)

In brief

The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).

Key facts

Study ID

NCT06588595

Run by

University of Florida

People needed

90

Starts

2024-11-01

Expected to finish

2027-02-28

Last updated by the study team

2026-02-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients who have undergone PCI and are on maintenance treatment with DAPT, composed of low-dose aspirin (81mg qd) with either prasugrel (10 mg qd) or ticagrelor (90 mg bid). In particular, patients who underwent PCI in the setting of an acute coronary syndrome will be eligible for randomization after ≥90 days post-PCI, while patients who underwent PCI in the setting of a chronic coronary syndrome ≥30 days post-PCI.
• Age ≥18 years
• Provide written informed consent.

You may not qualify if…

• Prior history of stent thrombosis
• PCI within 30 days
• On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban) or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
• Hemodynamic instability
• Hypersensitivity to clopidogrel
• Known platelet count less than 80x10\^6/mL
• Known hemoglobin less than 9 g/dL
• Pregnant and breastfeeding women [women of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study].

Where it is running

• University of Florida — Jacksonville, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.